CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Dupilumabdrug
Likely dose
Dupilumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03595488
NCT03595488Phase 2Completed
CompareCT.gov

Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)

Rochester General Hospital·interventional·Posted Jul 23, 2018·Updated Aug 26, 2020

In Brief

A Phase 2 clinical trial evaluating Dupilumab for Aspirin-exacerbated Respiratory Disease. Completed, enrolled 11 participants across 1 site.

Detailed Summary

Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain unacceptably symptomatic with a SNOT 22 score \> 18 despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAspirin-exacerbated Respiratory Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 23, 2018
Enrollment StartSep 5, 2018
Primary CompletionDec 11, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.9 years ago

Interventions

Dupilumabdrug

dupilumab 300 mg subcutaneous injection every 2 weeks